Texas

Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.

Although the concept of genome editing is just starting to gain traction, it has the potential to revolutionize health care by being able to treat, and in many cases cure, previously difficult-to-treat or untreatable genetic diseases. Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.

Pattern Bioscience was awarded funding from CARB-X to develop a new rapid diagnostic for drug-resistant bacterial infection.

Researchers are constantly finding drug combinations that help fight drug-resistant cancers. Researchers at the UT Southwestern Medical Center appeared to have found a new one using already approved drugs.

There were plenty of clinical trial announcements this week. Here’s a look.

A recent study questions if the FDA and other regulatory agencies worldwide rush certain approvals, particularly at the end of the year in a kind of “desk-clearing” activity.

BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.

“We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Savara’s chief executive officer.